Project Grant HT94252510853
Award Date 10/1/25
Completion Date 9/30/28
Dollars Obligated $1.3M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Houston, TX 77030, USA
Similar Awards
- This $1,431,215.00 federal Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports research at the University of Texas M.D. Anderson Cancer Center in Houston, TX. The grant is focused on building T-cell products to target malignant peripheral nerve sheath tumors (MPNSTs) associated with neurofibromatosis type 1 (NF1). The research aims to advance antigen discovery and epigenome targeting approaches to develop novel...
- This Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $489,767 to The University of Texas M.D. Anderson Cancer Center in Houston, TX to support research on building T-cell products for the treatment of NF1-associated malignant peripheral nerve sheath tumors (MPNST). The project aims to advance the understanding of MPNST through antigen discovery and epigenome targeting, with the goal of developing improved...
- The U.S. Department of Defense's Military Medical Research and Development program (CFDA 12.420) awarded a $931,113 project grant to The University of Texas MD Anderson Cancer Center, with a performance period from November 1, 2024 to October 31, 2027. The grant supports research targeting RNA surveillance machinery in neurofibromatosis type 1 (NF1)-mutant malignant peripheral nerve sheath tumors (MPNSTs). As a leading academic cancer research institution, MD Anderson has extensive expertise...
- This $505,071 Project Grant award from the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program supports research by the University of Texas MD Anderson Cancer Center to discover novel antigens in triple-negative breast cancer for the development of innovative T-cell therapies. The award period runs from February 15, 2025 to February 14, 2028, with the ultimate goal of transforming healthcare for military service members, veterans, and the broader...
- This $1,626,438 Project Grant award from the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program supports advanced biomedical research by the University of Texas MD Anderson Cancer Center to address critical health challenges for military service members, veterans, and the broader public. The funding will enable the cancer center to conduct diverse medical research investigations spanning basic, applied, and translational domains, with a focus on...
- This $414,472 federal Project Grant awarded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports research at The University of Texas M.D. Anderson Cancer Center to investigate neuronal mimicry in the treatment of SMARCB1-deficient renal medullary carcinoma. The 3-year award, effective from September 1, 2025 through August 31, 2028, will fund advanced biomedical research aimed at transforming healthcare for military service members,...
- The University of Texas MD Anderson Cancer Center received a $1,041,605 Project Grant award from the Department of Defense's Military Medical Research and Development program (CFDA 12.420) to conduct research titled "INTERROGATING TUMOR-IMMUNE-NEURON CROSS TALK AT SINGLE-CELL RESOLUTION IN A PANEL OF NOVEL SOMATIC TRANSGENIC NF1 TUMOR MODELS". This 3-year award, starting on September 1, 2023, will support basic and translational cancer research focused on understanding the interactions...
- This $1,619,723 federal Project Grant award from the Department of Defense's Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides funding to The University of Texas MD Anderson Cancer Center to conduct research targeting novel mediators of breast cancer brain metastasis. The award period runs from April 1, 2024 to March 31, 2027, with the goal of developing new treatments, improving patient care, and advancing scientific understanding in this...
- The University of Texas MD Anderson Cancer Center received a $567,000 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The grant, awarded on September 1, 2024, will fund research targeting myeloid mimicry in renal medullary carcinoma, with a completion date of August 31, 2027. Through this federal grant, MD Anderson Cancer Center will conduct innovative scientific studies, ranging from basic laboratory research to advanced...
- The University of Texas MD Anderson Cancer Center received a $647,990 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). This three-year grant, effective June 1, 2024, supports research to investigate cell plasticity and epigenetic reprogramming mechanisms underlying the transition of well-differentiated to de-differentiated liposarcoma. The funding will enable basic research, translational studies, and potentially future...